Deals in Depth: May 2008
Executive Summary
May 2008 dealmaking highlights: BMS stood out, getting a Phase II cardiovascular agent from KAI, selling off its ConvaTec wound healing division to private equity, and acquiring Kosan BioSciences; total private placement dollars in biopharma companies ($496mm) was almost half what it was in the previous month, while private investments in device players were up 67% to $278mm.You may also be interested in...
WHO To Clean Up Data Integrity Failings
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
Newron Not Seeing Sarizotan STARS Yet
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
Warning Letter Roundup & Recap – 10 December 2019
No device-related warning letters were released by the US FDA the week of 10 December.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports